IRBESARTAN IN THE CLINICAL PRACTICE
Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227965162848256 |
|---|---|
| author | V. I. Podzolkov A. I. Tarzimanova |
| author_facet | V. I. Podzolkov A. I. Tarzimanova |
| author_sort | V. I. Podzolkov |
| collection | DOAJ |
| description | Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented. |
| format | Article |
| id | doaj-art-c2edb2667d9d4bcf9c2f96dd6793b8bb |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-c2edb2667d9d4bcf9c2f96dd6793b8bb2025-08-23T10:00:18ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0110665966410.20996/1819-6446-2014-10-6-659-664306IRBESARTAN IN THE CLINICAL PRACTICEV. I. Podzolkov0A. I. Tarzimanova1I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityOnly few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented.https://www.rpcardio.online/jour/article/view/306irbesartanangiotensin receptor blockersarterial hypertensionnephroprotection |
| spellingShingle | V. I. Podzolkov A. I. Tarzimanova IRBESARTAN IN THE CLINICAL PRACTICE Рациональная фармакотерапия в кардиологии irbesartan angiotensin receptor blockers arterial hypertension nephroprotection |
| title | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_full | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_fullStr | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_full_unstemmed | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_short | IRBESARTAN IN THE CLINICAL PRACTICE |
| title_sort | irbesartan in the clinical practice |
| topic | irbesartan angiotensin receptor blockers arterial hypertension nephroprotection |
| url | https://www.rpcardio.online/jour/article/view/306 |
| work_keys_str_mv | AT vipodzolkov irbesartanintheclinicalpractice AT aitarzimanova irbesartanintheclinicalpractice |